Compare SHO & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHO | IOVA |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | United States | United States |
| Employees | 37 | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | 2008 |
| Metric | SHO | IOVA |
|---|---|---|
| Price | $11.48 | $3.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $9.79 | $9.00 |
| AVG Volume (30 Days) | 1.9M | ★ 12.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.95 | $47.74 |
| Revenue Next Year | $2.30 | $40.31 |
| P/E Ratio | $966.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.43 | $1.67 |
| 52 Week High | $11.71 | $5.63 |
| Indicator | SHO | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 72.80 | 49.17 |
| Support Level | $8.81 | $2.07 |
| Resistance Level | N/A | $4.27 |
| Average True Range (ATR) | 0.24 | 0.37 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 82.71 | 34.15 |
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in California which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its Hotel Ownership Segment.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.